AstraZeneca beefs-up cancer portfolio in all-cash $2 billion acquisition
Pharmaceutical giant AstraZeneca has agreed to buy Nasdaq-listed Fusion Pharmaceuticals (FUSN:NASDAQ) for around $2 billion in cash to boost its cancer portfolio.
The proposed deal is pitched at $21 per share, which is double the $10.64 closing price on 18 March. In US pre-market trading the shares were exchanging hands for around $20.4.
AstraZeneca described the deal as a 'major step forward...